I think we're in the early innings of what will become an evolving set of tools that many innovator drug companies may engage with to protect their assets, and this runs completely counter to the objectives of competition for biosimilars or for other innovative products.
Highlighting concerns about drug companies using legal strategies to hinder competition.
Share
More from Susan Collins
They don’t have them yet. The orders were placed, but they couldn’t [process] the orders when the government was shut down.
These allegations are appalling. Nevertheless, it is not up to me to choose the Democratic nominee for Senate.
Obviously, I'm going to be contrasting my record of achievement and accomplishments with Graham Platner's approach.
Other voices in this conversation
